APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceuticals in Nuclear Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2026-2032

26 December 2025198 pages

Choose your research edition.

Industry ResearchRadiopharmaceuticals in Nuclear Medicine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceuticals in Nuclear Medicine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.

Radiopharmaceuticals in Nuclear Medicine Segment by Company

Aurobindo Pharma

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

Mundipharma

Novartis

SIEMENS

Bayer

Dongcheng

Eli Lilly

China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals

Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology

Cardiology

Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Radiopharmaceuticals in Nuclear Medicine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiopharmaceuticals in Nuclear Medicine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Diagnostic Radiopharmaceuticals Major Manufacturers Table 3. Therapy Radiopharmaceuticals Major Manufacturers Table 4. Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Oncology Major Manufacturers Table 6. Cardiology Major Manufacturers Table 7. Other Major Manufacturers Table 8. Radiopharmaceuticals in Nuclear Medicine Industry Trends Table 9. Radiopharmaceuticals in Nuclear Medicine Industry Drivers Table 10. Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges Table 11. Radiopharmaceuticals in Nuclear Medicine Industry Restraints Table 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2026) Table 16. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2027-2032) Table 17. Global Radiopharmaceuticals in Nuclear Medicine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026) & (K Units) Table 19. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2027-2032) & (K Units) Table 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2026) Table 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2027-2032) Table 22. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Radiopharmaceuticals in Nuclear Medicine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application Table 30. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Radiopharmaceuticals in Nuclear Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2026) Table 37. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2027-2032) Table 38. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 40. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 41. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2026) Table 42. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2027-2032) Table 43. Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2026) & (US$/Unit) Table 44. Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2027-2032) & (US$/Unit) Table 45. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2026) Table 49. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2027-2032) Table 50. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 52. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 53. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2026) Table 54. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2027-2032) Table 55. Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2027-2032) & (US$/Unit) Table 57. Aurobindo Pharma Company Information Table 58. Aurobindo Pharma Business Overview Table 59. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 61. Aurobindo Pharma Recent Development Table 62. Bracco Imaging Company Information Table 63. Bracco Imaging Business Overview Table 64. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 66. Bracco Imaging Recent Development Table 67. Cardinal Health Company Information Table 68. Cardinal Health Business Overview Table 69. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 71. Cardinal Health Recent Development Table 72. Curium Pharma Company Information Table 73. Curium Pharma Business Overview Table 74. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 76. Curium Pharma Recent Development Table 77. GE Healthcare Company Information Table 78. GE Healthcare Business Overview Table 79. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 81. GE Healthcare Recent Development Table 82. Jubilant Pharma Company Information Table 83. Jubilant Pharma Business Overview Table 84. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 86. Jubilant Pharma Recent Development Table 87. Lantheus Company Information Table 88. Lantheus Business Overview Table 89. Lantheus Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 91. Lantheus Recent Development Table 92. Mundipharma Company Information Table 93. Mundipharma Business Overview Table 94. Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 96. Mundipharma Recent Development Table 97. Novartis Company Information Table 98. Novartis Business Overview Table 99. Novartis Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 101. Novartis Recent Development Table 102. SIEMENS Company Information Table 103. SIEMENS Business Overview Table 104. SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 106. SIEMENS Recent Development Table 107. Bayer Company Information Table 108. Bayer Business Overview Table 109. Bayer Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 111. Bayer Recent Development Table 112. Dongcheng Company Information Table 113. Dongcheng Business Overview Table 114. Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 116. Dongcheng Recent Development Table 117. Eli Lilly Company Information Table 118. Eli Lilly Business Overview Table 119. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 121. Eli Lilly Recent Development Table 122. China Isotope & Radiation Company Information Table 123. China Isotope & Radiation Business Overview Table 124. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 126. China Isotope & Radiation Recent Development Table 127. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 130. North America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 131. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 132. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 133. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 136. North America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 137. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 138. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 139. North America Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 144. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 145. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 146. North America Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 147. United States Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 148. Canada Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 149. Mexico Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 150. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 151. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 152. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 153. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 154. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 155. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 156. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 157. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 158. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 159. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 160. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 161. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 162. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 166. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 167. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 168. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 169. Europe Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 170. Germany Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 171. France Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 172. U.K. Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 173. Italy Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 174. Russia Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 175. Spain Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 176. Netherlands Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 177. Switzerland Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 178. Sweden Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 179. Poland Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 180. China Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 181. China Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 182. China Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 183. China Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 184. China Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 185. China Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 186. China Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 187. China Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 188. China Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 189. China Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 190. China Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 191. China Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 192. Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 193. Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 194. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 195. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 196. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 197. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 198. Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 199. Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 200. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 201. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 202. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 203. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 204. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 208. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 209. Asia Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 210. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 211. Asia Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Japan Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 213. South Korea Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 214. India Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 215. Australia Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 216. Taiwan Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 217. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 218. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 219. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 220. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 221. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 222. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2021-2026) & (US$/Unit) Table 223. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2027-2032) & (US$/Unit) Table 224. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 225. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 226. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 227. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 228. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2021-2026) & (US$/Unit) Table 229. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Application (2027-2032) & (US$/Unit) Table 230. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 231. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 232. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 233. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 234. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 235. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 236. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2021-2026) & (US$/Unit) Table 237. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Price by Country (2027-2032) & (US$/Unit) Table 238. Brazil Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 239. Argentina Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 240. Chile Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 241. Colombia Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 242. Peru Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 243. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 244. Israel Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 245. UAE Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 246. Turkey Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 247. Iran Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 248. Egypt Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Table 249. Key Raw Materials Table 250. Raw Materials Key Suppliers Table 251. Radiopharmaceuticals in Nuclear Medicine Distributors List Table 252. Radiopharmaceuticals in Nuclear Medicine Customers List Table 253. Research Programs/Design for This Report Table 254. Authors List of This Report Table 255. Secondary Sources Table 256. Primary Sources List of Figures Figure 1. Radiopharmaceuticals in Nuclear Medicine Image Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Diagnostic Radiopharmaceuticals Image Figure 5. Therapy Radiopharmaceuticals Image Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Radiopharmaceuticals in Nuclear Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Oncology Image Figure 9. Cardiology Image Figure 10. Other Image Figure 11. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue (2021-2032) & (US$ Million) Figure 13. Global Radiopharmaceuticals in Nuclear Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2032) Figure 16. Global Radiopharmaceuticals in Nuclear Medicine Sales (2021-2032) & (K Units) Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Radiopharmaceuticals in Nuclear Medicine Sales YoY (2021-2032) & (K Units) Figure 20. Europe Radiopharmaceuticals in Nuclear Medicine Sales YoY (2021-2032) & (K Units) Figure 21. China Radiopharmaceuticals in Nuclear Medicine Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Radiopharmaceuticals in Nuclear Medicine Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales YoY (2021-2032) & (K Units) Figure 24. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032) Figure 30. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032) Figure 33. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032) Figure 36. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032) Figure 39. North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2021-2032) Figure 40. North America Radiopharmaceuticals in Nuclear Medicine Sales Share by Type (2021-2032) Figure 41. North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2021-2032) Figure 42. North America Radiopharmaceuticals in Nuclear Medicine Sales Share by Application (2021-2032) Figure 43. North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country (2021-2032) Figure 44. North America Radiopharmaceuticals in Nuclear Medicine Sales Share by Country (2021-2032) Figure 45. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2021-2032) Figure 46. Europe Radiopharmaceuticals in Nuclear Medicine Sales Share by Type (2021-2032) Figure 47. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2021-2032) Figure 48. Europe Radiopharmaceuticals in Nuclear Medicine Sales Share by Application (2021-2032) Figure 49. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country (2021-2032) Figure 50. Europe Radiopharmaceuticals in Nuclear Medicine Sales Share by Country (2021-2032) Figure 51. China Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2021-2032) Figure 52. China Radiopharmaceuticals in Nuclear Medicine Sales Share by Type (2021-2032) Figure 53. China Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2021-2032) Figure 54. China Radiopharmaceuticals in Nuclear Medicine Sales Share by Application (2021-2032) Figure 55. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2021-2032) Figure 56. Asia Radiopharmaceuticals in Nuclear Medicine Sales Share by Type (2021-2032) Figure 57. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2021-2032) Figure 58. Asia Radiopharmaceuticals in Nuclear Medicine Sales Share by Application (2021-2032) Figure 59. Asia Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country (2021-2032) Figure 60. Asia Radiopharmaceuticals in Nuclear Medicine Sales Share by Country (2021-2032) Figure 61. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2021-2032) Figure 62. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Share by Type (2021-2032) Figure 63. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2021-2032) Figure 64. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Share by Application (2021-2032) Figure 65. SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country (2021-2032) Figure 66. SAMEA Radiopharmaceuticals in Nuclear Medicine Sales Share by Country (2021-2032) Figure 67. Radiopharmaceuticals in Nuclear Medicine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Radiopharmaceuticals in Nuclear Medicine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic Radiopharmaceuticals
  • Therapy Radiopharmaceuticals
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Aurobindo Pharma
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • Mundipharma
  • Novartis
  • SIEMENS
  • Bayer
  • Dongcheng
  • Eli Lilly
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Radiopharmaceuticals in Nuclear Medicine Market by Type
  3. 1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Diagnostic Radiopharmaceuticals
  5. 1.2.3 Therapy Radiopharmaceuticals
  6. 1.3 Radiopharmaceuticals in Nuclear Medicine Market by Application
  7. 1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Oncology
  9. 1.3.3 Cardiology
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
  1. 2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
  2. 2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
  3. 2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
  3. 3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2021-2026)
  5. 3.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2027-2032)
  6. 3.2.4 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
  9. 3.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026)
  11. 3.4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2027-2032)
  12. 3.4.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers
  2. 4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers
  6. 4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application
  13. 4.7 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
  16. 4.8.2 2025 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3
5 Radiopharmaceuticals in Nuclear Medicine Market by Type
  1. 5.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
  2. 5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
  6. 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type
6 Radiopharmaceuticals in Nuclear Medicine Market by Application
  1. 6.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
  2. 6.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
  6. 6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application
7 Company Profiles
  1. 7.1 Aurobindo Pharma
  2. 7.1.1 Aurobindo Pharma Company Information
  3. 7.1.2 Aurobindo Pharma Business Overview
  4. 7.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  6. 7.1.5 Aurobindo Pharma Recent Developments
  7. 7.2 Bracco Imaging
  8. 7.2.1 Bracco Imaging Company Information
  9. 7.2.2 Bracco Imaging Business Overview
  10. 7.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  12. 7.2.5 Bracco Imaging Recent Developments
  13. 7.3 Cardinal Health
  14. 7.3.1 Cardinal Health Company Information
  15. 7.3.2 Cardinal Health Business Overview
  16. 7.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  18. 7.3.5 Cardinal Health Recent Developments
  19. 7.4 Curium Pharma
  20. 7.4.1 Curium Pharma Company Information
  21. 7.4.2 Curium Pharma Business Overview
  22. 7.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  24. 7.4.5 Curium Pharma Recent Developments
  25. 7.5 GE Healthcare
  26. 7.5.1 GE Healthcare Company Information
  27. 7.5.2 GE Healthcare Business Overview
  28. 7.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  30. 7.5.5 GE Healthcare Recent Developments
  31. 7.6 Jubilant Pharma
  32. 7.6.1 Jubilant Pharma Company Information
  33. 7.6.2 Jubilant Pharma Business Overview
  34. 7.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  36. 7.6.5 Jubilant Pharma Recent Developments
  37. 7.7 Lantheus
  38. 7.7.1 Lantheus Company Information
  39. 7.7.2 Lantheus Business Overview
  40. 7.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  42. 7.7.5 Lantheus Recent Developments
  43. 7.8 Mundipharma
  44. 7.8.1 Mundipharma Company Information
  45. 7.8.2 Mundipharma Business Overview
  46. 7.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  48. 7.8.5 Mundipharma Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  54. 7.9.5 Novartis Recent Developments
  55. 7.10 SIEMENS
  56. 7.10.1 SIEMENS Company Information
  57. 7.10.2 SIEMENS Business Overview
  58. 7.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  60. 7.10.5 SIEMENS Recent Developments
  61. 7.11 Bayer
  62. 7.11.1 Bayer Company Information
  63. 7.11.2 Bayer Business Overview
  64. 7.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  66. 7.11.5 Bayer Recent Developments
  67. 7.12 Dongcheng
  68. 7.12.1 Dongcheng Company Information
  69. 7.12.2 Dongcheng Business Overview
  70. 7.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  72. 7.12.5 Dongcheng Recent Developments
  73. 7.13 Eli Lilly
  74. 7.13.1 Eli Lilly Company Information
  75. 7.13.2 Eli Lilly Business Overview
  76. 7.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  78. 7.13.5 Eli Lilly Recent Developments
  79. 7.14 China Isotope & Radiation
  80. 7.14.1 China Isotope & Radiation Company Information
  81. 7.14.2 China Isotope & Radiation Business Overview
  82. 7.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  84. 7.14.5 China Isotope & Radiation Recent Developments
8 North America
  1. 8.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Type
  2. 8.1.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  3. 8.1.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  4. 8.1.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
  5. 8.2 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Application
  6. 8.2.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  7. 8.2.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 8.2.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
  9. 8.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country
  10. 8.3.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Radiopharmaceuticals in Nuclear Medicine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Type
  2. 9.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  4. 9.1.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
  5. 9.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Application
  6. 9.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 9.2.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
  9. 9.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country
  10. 9.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Radiopharmaceuticals in Nuclear Medicine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Radiopharmaceuticals in Nuclear Medicine Market Size by Type
  2. 10.1.1 China Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  3. 10.1.2 China Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  4. 10.1.3 China Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
  5. 10.2 China Radiopharmaceuticals in Nuclear Medicine Market Size by Application
  6. 10.2.1 China Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  7. 10.2.2 China Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 10.2.3 China Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Type
  2. 11.1.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  4. 11.1.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
  5. 11.2 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Application
  6. 11.2.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 11.2.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
  9. 11.3 Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Country
  10. 11.3.1 Asia Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Radiopharmaceuticals in Nuclear Medicine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Type
  2. 12.1.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
  5. 12.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Application
  6. 12.2.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
  9. 12.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Market Size by Country
  10. 12.3.1 SAMEA Radiopharmaceuticals in Nuclear Medicine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Radiopharmaceuticals in Nuclear Medicine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
  2. 13.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
  6. 13.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
  9. 13.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst